Ikena Oncology Reports First Quarter 2024 Financial Results and Corporate Update [Yahoo! Finance]
Ikena Oncology, Inc. (IKNA)
Company Research
Source: Yahoo! Finance
IK-595 program continues dose escalation in patients with RAS and RAF mutant cancers BOSTON, May 13, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced financial results for the first quarter ended March 31, 2024. The Company also provided an update regarding its organization and pipeline. "We continue to execute thoughtfully and diligently on our clinical programs," said Mark Manfredi, Ph.D., Chief Executive Officer of Ikena. "With the dedication of our hyper-focused team and strong balance sheet, we are well positioned to build value for our shareholders by pursuing the development of novel, targeted therapies for patients.” Recent Pipeline Progress & Corporate Update IK-930: TEAD1-Selective Hippo Pathway Inhibitor The IK-930 clinical program continues to recruit patients with tumors harboring mutations in the Hippo pathway, with a focus o
Show less
Read more
Impact Snapshot
Event Time:
IKNA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IKNA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IKNA alerts
High impacting Ikena Oncology, Inc. news events
Weekly update
A roundup of the hottest topics
IKNA
News
- It's Unlikely That Ikena Oncology, Inc.'s (NASDAQ:IKNA) CEO Will See A Huge Pay Rise This Year [Yahoo! Finance]Yahoo! Finance
- Ikena Oncology, Inc. (NASDAQ: IKNA) was downgraded by analysts at Wedbush from an "outperform" rating to a "neutral" rating. They now have a $2.00 price target on the stock, down previously from $8.00.MarketBeat
- Ikena Oncology, Inc. (NASDAQ: IKNA) had its price target lowered by analysts at HC Wainwright from $11.00 to $4.00. They now have a "buy" rating on the stock.MarketBeat
- UPDATE – Ikena Oncology Announces Strategic UpdateGlobeNewswire
- Ikena Oncology Announces Strategic Update [Yahoo! Finance]Yahoo! Finance
IKNA
Earnings
- 3/12/24 - In-Line
IKNA
Sec Filings
- 6/10/24 - Form 4
- 6/10/24 - Form 4
- 6/10/24 - Form 4
- IKNA's page on the SEC website